Cerebrovascular reactivity in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations
Hoogeveen, E.S.; Pelzer, N.; Ghariq, E.; Osch, M.J.P. van; Dahan, A.; Terwindt, G.M.; Kruit, M.C.

Citation
Hoogeveen, E. S., Pelzer, N., Ghariq, E., Osch, M. J. P. van, Dahan, A., Terwindt, G. M., & Kruit, M. C. (2020). Cerebrovascular reactivity in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Journal Of Cerebral Blood Flow And Metabolism, 41(4), 831-840. doi:10.1177/0271678X20929430

Version: Publisher's Version
License: Creative Commons CC BY-NC 4.0 license
Downloaded from: https://hdl.handle.net/1887/3181304

Note: To cite this publication please use the final published version (if applicable).
Cerebrovascular reactivity in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations

Evelien S Hoogeveen1, Nadine Pelzer2, Eidrees Ghariq1,3, Matthias JP van Osch1,3, Albert Dahan4, Gisela M Terwindt2,* and Mark C Kruit1,*

Abstract
Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S) is a small vessel disease caused by TREX1 mutations. RVCL-S is characterized by retinal vasculopathy and brain white matter lesions with and without contrast enhancement. We aimed to investigate cerebrovascular reactivity (CVR) in RVCL-S. In this cross-sectional observational study, 21 RVCL-S patients, 23 mutation-negative family members, and 31 healthy unrelated controls were included. CVR to a hypercapnic challenge was measured using dual-echo arterial spin labeling magnetic resonance imaging. Stratified analyses based on age were performed. We found that CVR was decreased in gray and white matter of RVCL-S patients compared with family members and healthy controls (ANCOVA; \( P < 0.05 \) for all comparisons). This was most noticeable in RVCL-S patients aged \( \geq 40 \) years (ANCOVA, \( P < 0.05 \) for all comparisons). In RVCL-S patients aged \( < 40 \) years, only CVR in white matter was lower when compared to healthy controls (\( P < 0.05 \)). Gray matter CVR was associated with white matter lesion volume in RVCL-S patients (\( r = -0.527, P = 0.01 \)). In conclusion, impaired cerebrovascular reactivity may play an important role in the pathophysiology of RVCL-S and may be an useful early biomarker of cerebrovascular disease severity.

Keywords
Cerebrovascular circulation, cerebrovascular disorders, leukoencephalopathies, magnetic resonance imaging, mutation

Introduction
Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations (RVCL-S) is an autosomal dominantly inherited small vessel disease caused by heterozygous C-terminal frameshift mutations in the TREX1 gene.1,2 How exactly TREX1 mutations lead to disease is still unresolved, but vasculopathic changes seem the cornerstone behind most features. These features include almost always vascular retinopathy and multifocal brain white matter lesions (WMLs). Brain WMLs may show contrast enhancement, implicating disruption of the blood–brain barrier of the local vasculature. Brain WMLs may have associated vasogenic and/or cytotoxic edema and may change in size, incidentally leading to
the formation of a “pseudotumor”. Other RVCL-S features include migraine, kidney and liver disease, anemia, hypertension, subclinical hypothyroidism, and Raynaud’s phenomenon.1–6

The underlying systemic vasculopathy of medium and small caliber arteries in RVCL-S is pathologically characterized by irregular thickening and splitting of basement membranes, smooth muscle cell and pericyte degeneration, fibrinoid necrosis, adventitial fibrosis, and mural hyalinization with collagenous material.2 These changes lead to vessel wall thickening, luminal narrowing, and vessel obliteration. Brain WMLs around such blood vessels are characterized by areas of ischemic necrosis, reactive chronic inflammatory cell infiltrates, reactive astrocytosis, and myelin and axonal loss.2

A previous study showed reduced vascular reactivity and increased vascular stiffness in the brachial arteries of RVCL-S patients.7 But up until now, no study has evaluated cerebrovascular reactivity (CVR) in RVCL-S. We hypothesized that TREX1-related vasculopathy gradually leads to global reduced CVR. CVR is known as the cerebrovascular reserve capacity and is a marker for cerebrovascular health. It can be measured as change in cerebral blood flow (CBF) to a hypercapnic stimulus.8,9 While blood oxygenation level dependent (BOLD) magnetic resonance imaging (MRI) has been the most commonly used readout marker, it is not a direct measure of CBF. Arterial spin labeling (ASL) MRI directly measures CBF but a drawback is that it suffers from a low signal-to-noise ratio. ASL-MRI with a dual-echo readout module provides simultaneous acquisition of ASL and BOLD images.

To test the hypothesis of reduced CVR in RVCL-S patients, we assessed global and regional CVR to hypercapnia using ASL and BOLD MRI in RVCL-S patients with a proven TREX1 mutation and compared results to TREX1 mutation-negative family members and healthy unrelated controls.

Materials and methods

Participants

We included 47 family members from three Dutch RVCL-S families. TREX1 mutation status was determined in all individuals: 23 subjects had a mutation in the TREX1 gene and 24 did not. The genetic status of individuals was not disclosed to participants, unless clinically requested by a clinical geneticist or neurologist. Family members who proved not to have a TREX1 mutation served as a control group. Thirty-two healthy volunteers were included as an additional control group to exclude that other genetic variants than the mutations in the TREX1 gene might influence results for the family members without a TREX1 mutation. Exclusion criteria were age younger than 18 years, severe asthma and chronic obstructive pulmonary disease, and any contraindication to MRI. Additional exclusion criteria for healthy controls were (i) primary headache syndrome, (ii) history of transient ischemic attack or ischemic or hemorrhagic brain infarct, (iii) presence of multiple sclerosis, (neuro-)systemic lupus erythematosus, brain tumor, vascular malformation, or vasculitis, (iv) presence of hypertension, (v) presence of diabetes mellitus, (vi) history of severe carotid artery stenosis, (vii) kidney or liver disease, (viii) Raynaud’s syndrome, and (ix) presence of malignancy. All participants were asked not to eat or drink (except for water) at least four hours prior to the measurements and to refrain from smoking at least two hours before measurements. All participants were scanned between 17:00 and 21:00 h. The medical ethics committee of the Leiden University Medical Center approved the study, and all participants gave written, informed consent. Study was performed according to guidelines of the Declaration of Helsinki.

MRI data acquisition

All imaging procedures were performed on a 3.0 T clinical MRI system (Philips, Best, The Netherlands). A dynamic dual-echo pseudo continuous ASL scan was employed to monitor the response to the CO2 challenge with the following scan parameters: TR = 4100 ms, TE1/TE2 = 13/35 ms, label duration/ post-label delay = 1650/1525 ms, multi-slice single shot EPI with background suppression (inversion pulses at 1680 and 2760 ms), 15 slices, voxel-size = 3 × 3 × 7 mm, 75 pairs of label and control images, ascending slice acquisition-order. The labeling plane was placed perpendicular to the internal carotid arteries and the vertebral arteries. We further acquired a dual-echo M0 scan (TR = 2000 ms, TE1/TE2 = 13/35 ms, resolution of 80 × 80, flip angle 90°, voxel-size 3 × 3 mm, 15 slices of 7 mm), a T1blood scan (TR = 150 ms, TE = 11 ms, resolution 240 × 240, flip angle 95°, voxel-size 1 × 1 mm, 1 slice of 2 mm),10 and a 3D T1-weighted anatomical scan (TR = 9.8 ms, TE = 4.6 ms, flip angle 8°, voxel-size 1.15 × 1.15 mm, 130 slices of 1.2 mm).

CBF was calculated using the following equation11

\[
\text{CBF} = \frac{6000 \cdot \dot{\lambda} \cdot \Delta\text{ASL} \cdot e^{(T1\text{blood} / T1\text{blood})}}{2 \cdot a \cdot T1\text{blood} \cdot M0 \cdot (1 - e^{-\frac{\text{PLD}}{\text{τ}_{\text{ms}}}})},
\]

where partition coefficient \( \dot{\lambda} = 0.9; \) post-label delay (PLD) = 1.525 s (for the first acquired slice; the PLD was adjusted for subsequent slices according to the inter-slice interval) and \( \tau = 1.65 \text{s}. \) \( \Delta\text{ASL} \) is the
difference in signal intensity of the control image minus label image. $M_0$ is the longitudinal magnetization of arterial blood and was obtained by the M0 scan. To correct for potential differences in hematocrit, the T1 relaxation time of blood was obtained from the T1$_{\text{blood}}$ scan.\textsuperscript{10}

**CO$_2$ reactivity experiment**

During the MRI session, subjects wore a close-fitting gas mask over the mouth and nose with a constant gas delivery at 50 L/min. Gas composition was monitored using an O$_2$ and CO$_2$ analyzer (Datex Capnomac Ultima\textsuperscript{TM}). The paradigm of this 10-min CO$_2$ reactivity experiment consisted of three alternating blocks of normocapnia (21% O$_2$, 79% N$_2$) with two blocks of hypercapnia (21% O$_2$, 74% N$_2$, 5% CO$_2$). Values for end-tidal partial pressure of CO$_2$ (PetCO$_2$) were extracted from respiratory data. Blood pressure and normocapnia (21% O$_2$, 79% N$_2$) with two blocks experiment consisted of three alternating blocks of white matter BOLD time-course by computing the delay between the PetCO$_2$ measures and changes in BOLD signal. CVR was calculated performing a least-squares fit of the CBF or BOLD signals and the PetCO$_2$ time-course to a linear model. The computed slope was normalized to the baseline CBF or BOLD signal to express CVR in units of \%CBF/mmHg CO$_2$ or \%BOLD/mmHg CO$_2$. Baseline CBF was defined as the mean CBF during the three normocapnic blocks, while excluding the first 16 s from every block. Likewise, normocapnic and hypercapnic PetCO$_2$ values were defined from the normocapnic or hypercapnic blocks respectively, while excluding the first 16 s of every block.

Voxel-wise maps of CVR were acquired by performing a least-squares fit of the CBF and BOLD maps to the shifted PetCO$_2$ time-course.

**Statistical analysis**

Data are presented as mean ± SD or as number (percentage). For the demographic and clinical continuous variables, differences between groups were assessed by one-way analysis of variance; categorical variables were compared by the Kruskal–Wallis test. CVR data were compared between RVCL-S patients, mutation-negative family members, and healthy controls using analyses of covariance controlling for age and sex. To determine whether CVR is altered before development of characteristic RVCL-S features, analyses were repeated after stratification by age, i.e. splitting the subjects into a group aged < 40 years (generally without
or with only few clinical RVCL-S features) and aged ≥40 years (usually with characteristic clinical RVCL-S features).2,6

WML volumes were skewed and therefore logarithmically transformed. Correlation analyses were used to assess the association between CVR and WML volumes in the RVCL-S patients. Two-tailed P-values < 0.05 were considered significant.

For voxel-wise statistics, the FSL randomize tool with threshold-free cluster enhancement was used to perform permutation-based nonparametric testing (n = 5000 permutations). Voxel-wise analyses of CVR were performed using a whole brain (gray and white matter) approach on the BOLD data. Voxel-wise analyses of CVRCBF were restricted to gray matter because of the low signal-to-noise ratio of ASL in white matter. In order to exclude RVCL-S lesions from the analyses, the lesion masking tool was applied using the individual WML masks. Significance was set at a family wise error corrected P < 0.05.

Results

Of 47 RVCL-S family members, 23 subjects had a TREDI mutation. Two RVCL-S mutation carriers, one mutation-negative family member, and one healthy control were excluded from analyses because of coincidental (RVCL-S unrelated) findings on MRI or incomplete measurements. Thus, 21 RVCL-S patients, 23 mutation-negative family members, and 31 healthy controls were included for analyses. Baseline characteristics were compared (Table 1) and showed that hypertension was an exclusion criterion for healthy controls and hypertensive patients compared to their mutation-negative family members. Age, sex, BMI, and WMLs were similar between the groups. In the RVCL-S patients aged ≥40 years, young age hypertension, n (%) 11 (52) 11 (52) 18 (58) NS

Table 1. Baseline characteristics of study participants (n = 75).

|                     | RVCL-S (n = 21) | Family members (n = 23) | Healthy controls (n = 31) | P-value |
|---------------------|----------------|-------------------------|---------------------------|---------|
| Age (y)             | 44.5 ± 15      | 43.4 ± 12                | 45.4 ± 14                 | NS      |
| Female, n (%)       | 11 (52)        | 11 (52)                  | 18 (58)                   | NS      |
| Body mass index (kg/m²) | 23.7 ± 3       | 25.9 ± 4                 | 23.8 ± 3                  | NS      |
| Hypertension, n (%) | 8 (43)         | 6 (23)                   | 0                         | 0.002   |
| WMLs (mL), median (range) | 0.4 (0–26.8)   | 0.4 (0.1–25.5)           | 0.8 (0–7.2)               | NS*     |

Note: Data represent mean ± SD unless specified otherwise.

WMLs: white matter lesions; RVCL-S: Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations.

*Kruskal–Wallis test.

...
members ($r = -0.254$, $P = 0.2$). White matter $\text{CVR}_{\text{BOLD}}$ was not associated with age in RVCL-S patients ($r = -0.275$, $P = 0.2$), mutation-negative family members ($r = 0.286$, $P = 0.2$), or healthy controls ($r = -0.293$, $P = 0.1$). An outlier was found in the mutation-negative family member group for gray matter $\text{CVR}_{\text{CBF}}$ and white matter $\text{CVR}_{\text{BOLD}}$. Exclusion of this outlier changed the direction of the association between $\text{CVR}_{\text{CBF}}$ and age in mutation-negative family members ($r = -0.260$, $P = 0.2$), but otherwise did not influence the results (data not shown).

We assessed the association between WML volume and CVR within the RVCL-S group. The association between WML volume and gray matter $\text{CVR}_{\text{CBF}}$ was not significant ($r = 0.266$, $P = 0.2$) and was only weakly significant with white matter $\text{CVR}_{\text{BOLD}}$ ($r = 0.273$, $P = 0.2$).

### Table 2. Blood pressure, PetCO$_2$, and CBF values at normocapnia and hypercapnia in RVCL-S patients, mutation-negative family members, and healthy controls.

|                      | RVCL-S ($n = 21$) | Family members ($n = 23$) | Healthy controls ($n = 31$) | $P$-value |
|----------------------|-------------------|---------------------------|----------------------------|----------|
| **Systolic BP, normocapnia (mmHg)** | 132.6 ± 19 | 125.6 ± 14* | 125.0 ± 13* | 0.02    |
| **Diastolic BP, normocapnia (mmHg)** | 76.0 ± 11 | 77.4 ± 8  | 73.2 ± 7   | 0.05    |
| **Systolic BP, hypercapnia (mmHg)** | 135.9 ± 24 | 128.7 ± 15 | 128.0 ± 14* | 0.03    |
| **Diastolic BP, hypercapnia (mmHg)** | 80.1 ± 12 | 81.8 ± 9  | 76.5 ± 8*  | 0.03    |
| **PetCO$_2$, normocapnia (mmHg)** | 37.6 ± 3  | 38.3 ± 4  | 38.5 ± 3   | 0.33    |
| **PetCO$_2$, hypercapnia (mmHg)** | 46.8 ± 3  | 47.5 ± 3  | 48.2 ± 2   | 0.07    |
| **$\Delta$ PetCO$_2$ (mmHg)** | 9.2 ± 1   | 9.2 ± 1   | 9.7 ± 1    | 0.35    |
| **CBF, normocapnia (mL/100 g/min)** | 55.3 ± 8  | 49.3 ± 8* | 46.3 ± 6*  | <0.001  |

BP: blood pressure; PetCO$_2$: partial pressure of end tidal CO$_2$; CBF: cerebral blood flow; RVCL-S: Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations.

Note: $P$-values are calculated using ANCOVA corrected for age and sex.

*a* $P < 0.05$ compared to RVCL-S patients.

*b* $P < 0.001$ compared to RVCL-S patients.

### Table 3. Cerebrovascular reactivity in RVCL-S patients, mutation-negative family members, and healthy controls.

|          | RVCL-S | Family member | Healthy control | $P$-value |
|----------|--------|---------------|-----------------|----------|
| **All, n** | 21     | 23            | 31              |          |
| **Gray matter** |        |               |                 |          |
| $\text{CVR}_{\text{CBF}}$ | 2.9 ± 1.0 | 3.6 ± 1.2* | 3.4 ± 1.0* | 0.03    |
| $\text{CVR}_{\text{BOLD}}$ | 0.16 ± 0.05 | 0.19 ± 0.04* | 0.18 ± 0.04* | **0.002** |
| **White matter** |       |               |                 |          |
| $\text{CVR}_{\text{BOLD}}$ | 0.06 ± 0.02 | 0.08 ± 0.02* | 0.08 ± 0.02* | <0.001  |
| **< 40 years, n** | 10     | 6             | 10              |          |
| **Gray matter** |        |               |                 |          |
| $\text{CVR}_{\text{CBF}}$ | 3.6 ± 1.0 | 3.7 ± 0.4    | 3.8 ± 1.3    | 0.6     |
| $\text{CVR}_{\text{BOLD}}$ | 0.18 ± 0.04 | 0.20 ± 0.05 | 0.22 ± 0.05 | 0.2     |
| **White matter** |       |               |                 |          |
| $\text{CVR}_{\text{BOLD}}$ | 0.07 ± 0.01 | 0.07 ± 0.02 | 0.09 ± 0.02* | **0.003** |
| **≥ 40 years, n** | 11     | 17            | 21              |          |
| **Gray matter** |        |               |                 |          |
| $\text{CVR}_{\text{CBF}}$ | 2.3 ± 0.8 | 3.6 ± 1.4*   | 3.2 ± 0.9*   | **0.02** |
| $\text{CVR}_{\text{BOLD}}$ | 0.13 ± 0.05 | 0.19 ± 0.03* | 0.16 ± 0.03* | **0.004** |
| **White matter** |       |               |                 |          |
| $\text{CVR}_{\text{BOLD}}$ | 0.05 ± 0.03 | 0.08 ± 0.02* | 0.08 ± 0.02* | **0.001** |

RVCL-S: Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations; CVR: cerebrovascular reactivity; CBF: cerebral blood flow; BOLD: blood oxygenation level dependent.

Notes: Data represent mean ± SD. $P$-values are calculated using ANCOVA corrected for age and sex.

*a* $P < 0.05$ compared to RVCL-S patients.

*b* $P < 0.001$ compared to RVCL-S patients.
significant \((r = -0.527, P = 0.01)\) and there was a trend for gray matter CVR\(_{\text{CBF}}\) \((r = -0.408; P = 0.07)\). The association between WML volume and white matter CVR\(_{\text{CBF}}\) did not reach statistical significance \((r = -0.317, P = 0.2)\) (Figure 2).

After exclusion of WMLs, voxel-wise analyses showed a significant reduction in CVR in multiple normal appearing brain areas, most notably in the frontal and parietal white matter, the thalamus and midbrain, and frontal, insular and precuneal cortical areas of RVCL-S patients compared to both mutation-negative family members and healthy controls (Figure 3). In gray matter, there is considerable overlap in the voxel-wise CVR\(_{\text{CBF}}\) and CVR\(_{\text{BOLD}}\) statistical maps. However some regional differences can be appreciated. CVR\(_{\text{BOLD}}\) findings are more explicit in the frontal regions, while CVR\(_{\text{CBF}}\) changes are more present in the occipital regions (Figure 3).

**Discussion**

The results of the present study indicate that RVCL-S patients are associated with impaired CVR compared with their mutation-negative family members and healthy controls. This was most notable in RVCL-S patients aged \(\geq 40\) years, when clinical symptoms usually manifest.\(^2,6\) However, also RVCL-S patients \(< 40\) years showed reduced white matter CVR compared with healthy controls. Gray matter CVR was inversely associated with WML volume in RVCL-S patients. Collectively, our findings support the notion that RVCL-S TREX1 mutations are associated with altered CVR which in turn may promote development of WMLs in RVCL-S.

CVR defines the ability to change CBF in response to vasodilatory stimuli. Increased arterial CO\(_2\) levels lead to vascular relaxation and hence vasodilation.\(^1,4\) A previous study showed that CO\(_2\) CVR can be considered a surrogate marker of cerebrovascular endothelial function.\(^15\) Thus, our findings of reduced CO\(_2\) CVR suggests endothelial involvement in RVCL-S patients. Our data add to previous studies in RVCL-S families where RVCL-S patients exhibited a decreased extra-cranial flow-mediated dilation corresponding with impaired peripheral endothelial function\(^7\) and had elevated levels of circulating endothelial markers,\(^16\) thereby suggesting an important role of the endothelium in the pathophysiology of RVCL-S. The current findings indicate a similar behavior of the extra- and intracranial vasculature in RVCL-S.

Although characteristic enhancing RVCL-S WMLs are mostly seen after the age of 40 years, small focal WMLs are also observed at an age when age-related WMLs are infrequent.\(^2\) We hypothesize that impaired white matter CVR leads to development of WMLs by poorer responses when metabolic needs require a higher blood supply. Impaired CVR may reflect the TREX1-associated vessel wall changes characterized by multi-laminated capillary basement membranes and luminal narrowing.\(^2,3\) These vessel wall changes may also lead to development of WMLs by injury of the surrounding brain tissue by toxic agents which pass a locally impaired blood–brain barrier.

Gray matter CVR was only impaired in RVCL-S patients \(\geq 40\) years, but not in the younger group. Neuropathology findings in RVCL-S show vasculopathic changes notably in medium and small caliber arteries and veins in the white matter with typical sparing of cortical gray matter vessels.\(^5\) Based on our findings, the cortical gray matter vessels are probably affected in later disease stages of RVCL-S. We also know from literature that other RVCL-S features such as chronic hypertension and anemia may contribute to decreased gray matter CVR.\(^17,18\) The increased mean baseline CBF in the RVCL-S group might also be explained by anemia or increased blood pressure.\(^18,19\) Since hypertension and anemia are features of RVCL-S, we could not correct for this in our analyses nor can we exclude that this may be (one of the) causes of the decreased CVR.

Although only gray matter CVR\(_{\text{BOLD}}\) was correlated with WML volume, a trend was observed in gray matter CVR\(_{\text{CBF}}\) (Figure 2). Moreover, using additional voxel-wise analyses, we showed that CVR is mainly reduced in the (normal appearing) white matter of the frontoparietal regions (Figure 3), where RVCL-S lesions predominantly develop.\(^2,20\)

In the past, BOLD has been the most commonly used readout marker for assessing CVR. However, a well-known concern is that the BOLD signal is not a direct measure of CBF but is sensitive to the combined effect of CBF, cerebral blood volume, and cerebral metabolic rate of oxygen. In patients with known small vessel pathology, this might limit our ability to interpret the results. ASL-MRI directly measures CBF but a drawback is that it suffers from a lower signal-to-noise ratio. Therefore, ASL and BOLD are complementary to each other, which was why in our study, a dual echo ASL sequence was employed. In Table 3, both gray matter CVR\(_{\text{CBF}}\) and CVR\(_{\text{BOLD}}\) were impaired in RVCL-S patients. This suggests that CVR\(_{\text{BOLD}}\) with a hypercapnic stimulus is largely related to changes in CBF and that both measures can be used interchangeably in RVCL-S.

The voxel-wise analyses in Figure 3 show some regional differences between the statistical maps of CVR\(_{\text{CBF}}\) and CVR\(_{\text{BOLD}}\). This can be partly explained by the fact that for the voxel-wise CVR\(_{\text{BOLD}}\) analyses, both gray and white matter were included, whereas the white matter was masked out for the CVR\(_{\text{CBF}}\) analyses. In gray matter, there is considerable overlap in the
Voxel-wise CVR CBF and CVR BOLD statistical maps but there are also some regional differences. This may be attributed to the higher signal-to-noise ratio of BOLD. Moreover, in a previous study in healthy subjects with a hypercapnic challenge, regional differences were shown between CVR BOLD and CVR CBF. Both measures correlated well in the frontal and temporal region, but were different in the parietal and occipital regions, probably reflecting the regionally distinct physiology of ASL and BOLD.

In Figure 1, we show that gray matter CVR BOLD but not white matter CVR BOLD decreased significantly with age in healthy controls, which is consistent with a previous study in healthy subjects. In RVCL-S patients,

![Figure 1](image1.png)

**Figure 1.** Cerebrovascular reactivity in relation to age in RVCL-S patients (n = 21), mutation-negative family members (n = 23), and healthy controls (n = 31).

CBF: cerebral blood flow; PetCO2: partial pressure of end tidal CO2; CVR: cerebrovascular reactivity; BOLD: blood oxygenation level dependent; RVCL-S: Retinal Vasculopathy with Cerebral Leukoencephalopathy and Systemic manifestations.

![Figure 2](image2.png)

**Figure 2.** Correlation of white matter lesion volume with cerebrovascular reactivity in RVCL-S patients (n = 21). WML: white matter lesion; CVR: cerebrovascular reactivity.
gray matter CVR\textsubscript{BOLD} also decreased with age, which can also be explained by advancing disease.

Strengths of this study include a unique sample of patients with RVCL-S that can be considered as a model for stroke and vascular dementia. Furthermore, to improve the accuracy of ASL-derived CBF measurements, the T1-relaxation time of blood was individually modeled as opposed to a fixed value in order to correct for differences in hematocrit.\textsuperscript{10} Our study also has some limitations. Because RVCL-S is a rare disease, the sample size is relatively small. Moreover, it is difficult to define RVCL-S patients as asymptomatic versus symptomatic due to the many systemic features that may be part of the disease. Therefore, we chose to stratify by the age of 40, when clinical symptoms usually manifest.\textsuperscript{2,6} Finally, due to the cross-sectional design, we cannot prove a causal relationship between CVR and WML volume in RVCL-S patients. Future
Conclusions

In conclusion, RVCL-S patients are associated with impaired CVR, a marker for cerebrovascular reserve capacity and cerebrovascular health. Moreover, gray matter CVR was inversely associated with brain WML volume in RVCL-S patients. These results further confirm the important role of the underlying vasculopathy in the pathophysiology of RVCL-S. CVR may be a useful early biomarker of disease severity. Future longitudinal studies are needed to assess whether CVR predicts development of typical brain RVCL-S lesions.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants of the Netherlands Organization for Scientific Research (NWO) (VIDI 91711319 to GMT) and the European Community (EC) (FP7-EUROHEADPAIN—no. 602633 to GMT); the funding agencies had no role in the design or conduct of the study.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ESH, NP, EG, AD, and MCK report no disclosures; MJPO reports speaker honoraria from Philips and independent support from NWO Domain Applied and Engineering Sciences, the European Community, and the Dutch Heart Foundation; and GMT reports independent support from NWO, ZonMW, European Community, Dutch Heart Foundation, and Dutch Brain Foundation.

Authors’ contributions

ESH contributed to the conception and design of the study, data acquisition, analysis, and interpretation of the data, and drafting the manuscript; NP contributed to the conception and design of the study, data acquisition, and revising the manuscript; EG contributed to the design of the study, analysis and interpretation of the data, and revising the manuscript; AD contributed to the design of the study and revising the manuscript; MJPO contributed to the design of the study, analysis and interpretation of the data, and revising the manuscript; AD contributed to the design of the study and revising the manuscript; and GMT contributed to the conception and design of the study, interpretation of the data, and revising the manuscript; MCK contributed to the conception and design of the study, analysis and interpretation of the data, and revising the manuscript; and GMT contributed to the conception and design of the study, analysis and interpretation of the data, and revising the manuscript; and GMT contributed to the conception and design of the study, and revising the manuscript.

References

1. Richards A, Van den Maagdenberg AM, Jen JC, et al. C-terminal truncations in human 3’-5’ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007; 39: 1068–1070.
2. Stam AH, Kothari PH, Shaikh A, et al. Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain 2016; 139: 2909–2922.
3. Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy, and stroke (HERNS). Neurology 1997; 49: 1322–1330.
4. Terwindt GM, Haan J, Ophoff RA, et al. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud’s phenomenon. Brain 1998; 121: 303–316.
5. Kolar GR, Kothari PH, Khanlou N, et al. Neuropathology and genetics of cerebroretinal vasculopathies. Brain Pathol 2014; 24: 510–518.
6. Pelzer N, Hoogeveen ES, Haan J, et al. Systemic features of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a monogenic small vessel disease. J Intern Med 2019; 285: 317–332.
7. De Boer I, Stam AH, Buntinx L, et al. RVCL-S and CADASIL display distinct impaired vascular function. Neurology 2018; 91: e956–e963.
8. Blockley NP, Driver ID, Francis ST, et al. An improved method for acquiring cerebrovascular reactivity maps. Magn Reson Med 2011; 65: 1278–1286.
9. Yezhuvath US, Uf J, Cheng Y, et al. Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer’s disease. Neurobiol Aging 2012; 33: 75–82.
10. Varela M, Hajnal JV, Petersen ET, et al. A method for rapid in vivo measurement of blood T1. NMR Biomed 2011; 24: 80–88.
11. Alsop DC, Detre JA, Golay X, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med 2015; 73: 102–116.
12. Jenkinson M, Beckmann CF, Behrens TE, et al. FSL. Neuroimage 2012; 62: 782–790.
13. Kitazono T, Faraci FM, Taguchi H, et al. Role of potassium channels in cerebral blood vessels. Stroke 1995; 26: 1713–1723.
14. Nelson MT and Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995; 268: C799–C822.
15. Lavi S, Gaitini D, Milloul V, et al. Impaired cerebral CO2 vasoreactivity: association with endothelial...
15. Dysfunction. *Am J Physiol Heart Circ Physiol* 2006; 291: H1856–H1861.

16. Pelzer N, Bijkerk R, Reinders MEJ, et al. Circulating endothelial markers in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. *Stroke* 2017; 48: 3301–3307.

17. Settakis G, Pall D, Molnar C, et al. Cerebrovascular reactivity in hypertensive and healthy adolescents: TCD with vasodilatory challenge. *J Neuroimaging* 2003; 13: 106–112.

18. Vorstrup S, Lass P, Waldemar G, et al. Increased cerebral blood flow in anemic patients on long-term hemodialytic treatment. *J Cereb Blood Flow Metab* 1992; 12: 745–749.

19. Gasparovic C, Qualls C, Greene ER, et al. Blood pressure and vascular dysfunction underlie elevated cerebral blood flow in systemic lupus erythematosus. *J Rheumatol* 2012; 39: 752–758.

20. Grand MG, Kaine J, Fulling K, et al. Cerebroretinal vasculopathy. A new hereditary syndrome. *Ophthalmology* 1988; 95: 649–659.

21. Zhou Y, Rodgers ZB and Kuo AH. Cerebrovascular reactivity measured with arterial spin labeling and blood oxygen level dependent techniques. *Magn Reson Imaging* 2015; 33: 566–576.

22. Bhogal AA, De Vis JB, Siero JCW, et al. The BOLD cerebrovascular reactivity response to progressive hypercapnia in young and elderly. *Neuroimage* 2016; 139: 94–102.